Review

Targeted Oncology

, Volume 7, Issue 3, pp 183-188

Profiling mTOR pathway in neuroendocrine tumors

  • S. CingarliniAffiliated withSection of Medical Oncology, Department of Medicine, Azienda Ospedaliera Universitaria Integrata (AOUI) Email author 
  • , M. BonomiAffiliated withSection of Medical Oncology, Department of Medicine, Azienda Ospedaliera Universitaria Integrata (AOUI)
  • , V. CorboAffiliated withARC-NET Research Centre and Department of Pathology and Diagnostic, Azienda Ospedaliera Universitaria Integrata (AOUI)
  • , A. ScarpaAffiliated withARC-NET Research Centre and Department of Pathology and Diagnostic, Azienda Ospedaliera Universitaria Integrata (AOUI)
  • , G. TortoraAffiliated withSection of Medical Oncology, Department of Medicine, Azienda Ospedaliera Universitaria Integrata (AOUI)

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The serine/threonine kinase mammalian target of rapamycin (mTOR) plays a central role in regulating critical cellular processes such as growth, proliferation, and protein synthesis. The study of cancer predisposing syndromes within which neuroendocrine tumors (NETs) may arise has furnished clues on the involvement of mTOR pathway in sporadic diseases so far. Recent comprehensive analyses have definitely shown activation of mTOR pathway in both experimental and human sporadic NETs. Upstream regulators of mTOR (PTEN and TSC2) have been found mutated in sporadic pNETs. Activation of mTOR pathways in NETs is already demonstrated by expression profiles analysis that revealed downregulation of TSC2 gene and alterations of TSC2 and PTEN protein expression in the vast majority of well-differentiated tumors. Moreover, a global microRNA expression analysis revealed the overexpression, in highly aggressive tumors, of a microRNA (miR-21) that targets PTEN reducing its expression and therefore leading to mTOR activation as well. Overall, these clues have furnished the rationale for the use of mTOR inhibitors the treatment of pNETs. With the recent approval of Everolimus (mTOR-targeted drug) for the treatment of advanced pNETs, this paradigm has been effectively translated into the clinical setting. In this review, we discuss mTOR pathway involvement in NETs, the clinical evidence supporting the use of mTOR inhibitors in cancer treatment, and the current clinical issues that remain to be elucidated to improve patient management.

Keywords

Neuroendocrine tumors PI3K Akt TSC2 PTEN mTOR